|
1
|
Bierie B and Moses HL: Tumour
microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ikushima H and Miyazono K: TGFbeta
signalling: a complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelstein B, Papadopoulos N, Velculescu
VE, et al: Cancer genome landscapes. Science. 339:1546–1558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fukuchi M, Miyazaki T, Fukai Y, et al:
Plasma level of transforming growth factor beta1 measured from the
azygos vein predicts prognosis in patients with esophageal cancer.
Clin Cancer Res. 10:2738–2741. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maehara Y, Kakeji Y, Kabashima A, et al:
Role of transforming growth factor-beta 1 in invasion and
metastasis in gastric carcinoma. J Clin Oncol. 17:607–614.
1999.PubMed/NCBI
|
|
7
|
Tsushima H, Kawata S, Tamura S, et al:
High levels of transforming growth factor beta 1 in patients with
colorectal cancer: association with disease progression.
Gastroenterology. 110:375–382. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsushima H, Ito N, Tamura S, et al:
Circulating transforming growth factor beta 1 as a predictor of
liver metastasis after resection in colorectal cancer. Clin Cancer
Res. 7:1258–1262. 2001.PubMed/NCBI
|
|
9
|
Narai S, Watanabe M, Hasegawa H, et al:
Significance of transforming growth factor beta1 as a new tumor
marker for colorectal cancer. Int J Cancer. 97:508–511. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Angenete E, Langenskiöld M, Palmgren I, et
al: Transforming growth factor beta-1 in rectal tumour, mucosa and
plasma in relation to radiotherapy and clinical outcome in rectal
cancer patients. Int J Colorectal Dis. 22:1331–1338. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shirai Y, Kawata S, Ito N, et al: Elevated
levels of plasma transforming growth factor-beta in patients with
hepatocellular carcinoma. Jpn J Cancer Res. 83:676–679. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shirai Y, Kawata S, Tamura S, et al:
Plasma transforming growth factor-beta 1 in patients with
hepatocellular carcinoma. Comparison with chronic liver diseases.
Cancer. 73:2275–2279. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ito N, Kawata S, Tamura S, et al: Positive
correlation of plasma transforming growth factor-beta1 levels with
tumor vascularity in hepatocellular carcinoma. Cancer Lett.
89:45–48. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song BC, Chung YH, Kim JA, et al:
Transforming growth factor-beta1 as a useful serologic marker of
small hepatocellular carcinoma. Cancer. 94:175–180. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okumoto S, Hattori E, Tamura K, et al:
Possible contribution of circulating transforming growth
factor-beta1 to immunity and prognosis in unresectable
hepatocellular carcinoma. Liver Int. 24:21–28. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong ZZ, Yao DF, Yao M, et al: Clinical
impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in
diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis
Int. 7:288–295. 2008.PubMed/NCBI
|
|
17
|
Soliman GM, Mohammed K, Taha A and Barrak
AA: The role of plasma transforming growth factor beta-1 in the
development of fibrosis in patient with HCV related
steatohepatitis. J Egypt Soc Parasitol. 40:759–772. 2010.PubMed/NCBI
|
|
18
|
Kong FM, Washington MK, Jirtle RL and
Anscher MS: Plasma transforming growth factor-beta 1 reflects
disease status in patients with lung cancer after radiotherapy: a
possible tumor marker. Lung Cancer. 16:47–59. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong FM, Jirtle RL, Huang DH, Clough RW
and Anscher MS: Plasma transforming growth factor-beta1 level
before radiotherapy correlates with long term outcome of patients
with lung carcinoma. Cancer. 86:1712–1719. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vujaskovic Z and Groen HJ: TGF-beta,
radiation-induced pulmonary injury and lung cancer. Int J Radiat
Biol. 76:511–516. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wakefield LM, Letterio JJ, Chen T, et al:
Transforming growth factor-beta1 circulates in normal human plasma
and is unchanged in advanced metastatic breast cancer. Clin Cancer
Res. 1:129–136. 1995.PubMed/NCBI
|
|
22
|
Murase T, Anscher MS, Petros WP, Peters WP
and Jirtle RL: Changes in plasma transforming growth factor beta in
response to high-dose chemotherapy for stage II breast cancer:
possible implications for the prevention of hepatic veno-occlusive
disease and pulmonary drug toxicity. Bone Marrow Transplant.
15:173–178. 1995.PubMed/NCBI
|
|
23
|
Kong FM, Anscher MS, Murase T, et al:
Elevated plasma transforming growth factor-beta 1 levels in breast
cancer patients decrease after surgical removal of the tumor. Ann
Surg. 222:155–162. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ivanović V, Demajo M, Krtolica K, et al:
Elevated plasma TGF-beta1 levels correlate with decreased survival
of metastatic breast cancer patients. Clin Chim Acta. 371:191–193.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nikolić-Vukosavljević D, Todorović-Raković
N, Demajo M, et al: Plasma TGF-beta1-related survival of
postmenopausal metastatic breast cancer patients. Clin Exp
Metastasis. 21:581–585. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grau AM, Wen W, Ramroopsingh DS, et al:
Circulating transforming growth factor-beta-1 and breast cancer
prognosis: results from the Shanghai Breast Cancer Study. Breast
Cancer Res Treat. 112:335–341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chod J, Zavatova E, Halaska MJ, et al:
Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma
levels in operable breast cancer patients. Eur J Gynaecol Oncol.
29:613–616. 2008.PubMed/NCBI
|
|
28
|
Todorović-Raković N,
Nesković-Konstantinović Z and Nikolić-Vukosavljević D:
Stage-related plasma values of transforming growth factor-beta1 are
steroid receptors dependent. Clin Exp Med. 9:313–317. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thomas DA and Massagué J: TGF-beta
directly targets cytotoxic T cell functions during tumor evasion of
immune surveillance. Cancer Cell. 8:369–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Harada M, Matsunaga K, Oguchi Y, et al:
The involvement of transforming growth factor beta in the impaired
antitumor T-cell response at the gut-associated lymphoid tissue
(GALT). Cancer Res. 55:6146–6151. 1995.PubMed/NCBI
|
|
31
|
Harada M, Matsunaga K, Oguchi Y, et al:
Oral administration of PSK can improve the impaired anti-tumor
CD4+ T-cell response in gut-associated lymphoid tissue
(GALT) of specific-pathogen-free mice. Int J Cancer. 70:362–372.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakazato H, Koike A, Saji S, Ogawa N and
Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment
after curative resection of gastric cancer. Study Group of
Immunochemotherapy with PSK for Gastric Cancer. Lancet.
343:1122–1126. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sakamoto J, Morita S, Oba K, et al:
Meta-Analysis Group of the Japanese Society for Cancer of the Colon
Rectum: Efficacy of adjuvant immunochemotherapy with polysaccharide
K for patients with curatively resected colorectal cancer: a
meta-analysis of centrally randomized controlled clinical trials.
Cancer Immunol Immunother. 55:404–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Japanese Gastric Cancer Association, .
Japanese Classification of Gastric Carcinoma - 2nd English Edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hidaka H, Nakazawa T, Shibuya A, et al:
Effects of 1-year administration of olmesartan on portal pressure
and TGF-beta1 in selected patients with cirrhosis: a randomized
controlled trial. J Gastroenterol. 46:1316–1323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsunaga K, Hosokawa A, Oohara M, et al:
Direct action of a protein-bound polysaccharide, PSK, on
transforming growth factor-beta. Immunopharmacology. 40:219–230.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Huang J, Ren X, et al: Abrogation
of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+
myeloid cells that promote metastasis. Cancer Cell. 13:23–35. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maehara Y, Tsujitani S, Saeki H, et al:
Biological mechanism and clinical effect of protein-bound
polysaccharide K (KRESTIN(®)): review of development and future
perspectives. Surg Today. 42:8–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Disis ML: National Center for
Complementary and Alternative Medicine (NCCAM). Bastyr/UW
Oncomycology Translational Research Center. http://nccam.nih.gov/training/centers/descriptions.htm#%23bastyr
|
|
41
|
Lu H, Yang Y, Gad E, et al: Polysaccharide
krestin is a novel TLR2 agonist that mediates inhibition of tumor
growth via stimulation of CD8 T cells and NK cells. Clin Cancer
Res. 17:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu H, Yang Y, Gad E, et al: TLR2 agonist
PSK activates human NK cells and enhances the antitumor effect of
HER2-targeted monoclonal antibody therapy. Clin Cancer Res.
17:6742–6753. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kono K, Kawaguchi Y, Mizukami Y, et al:
Protein-bound polysaccharide K partially prevents apoptosis of
circulating T cells induced by anti-cancer drug S-1 in patients
with gastric cancer. Oncology. 74:143–149. 2008. View Article : Google Scholar : PubMed/NCBI
|
